New tracer injection could sharpen cancer detection in lymph nodes
NCT ID NCT02285192
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 24 times
Summary
This study tests whether injecting a radioactive sugar tracer (18F-FDG) into the cervix before a PET/CT scan can better show which pelvic lymph nodes contain cancer in women with early-stage cervical or high-grade endometrial cancer. The goal is to improve surgical planning by more accurately mapping cancer spread. The trial involves 42 women and compares imaging results with lab analysis of removed lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Consent only)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Consent only)
Commack, New York, United States
-
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent only)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York, 10604, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Fluorodeoxyglucose (18F-FDG)
What this could lead to
If successful, this could provide a more accurate way to map cancer spread to lymph nodes, helping surgeons remove the right nodes and potentially improving treatment planning.
What could go wrong
This is a small, early-phase study with only 42 participants, so results may not apply to all patients. The technique is still experimental and may not be more accurate than current methods.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.